Payment overview · 2025
General Payments
$52.13
3 reported records · 2 companies
Healthcare provider profile · identity verified
Narain D Mandhan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MONTICELLO, IL · NPI 1730170655
Verified facts
What the public records show
CMS Open Payments records show Narain D Mandhan, M.D. received $52.13 in general payments during 2025 across 3 reported records.
Amgen Inc. accounted for 57.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.05 | 57.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.08 | 42.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $52.13 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.05 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.05 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 122 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 322 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 62 |
| Losartan Potassium | Losartan Potassium | 225 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 49 |
| Gabapentin | Gabapentin | 191 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 186 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 43 |
| Metformin Hcl Er | Metformin Hcl | 130 | 32 |
| Eliquis | Apixaban | 122 | 23 |
| Warfarin Sodium | Warfarin Sodium | 120 | 13 |
| Mounjaro | Tirzepatide | 119 | 18 |
| Potassium Chloride | Potassium Chloride | 117 | 23 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 116 | 116 |
| Sertraline Hcl | Sertraline Hcl | 113 | 22 |
| Lisinopril | Lisinopril | 112 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 22 |
| Montelukast Sodium | Montelukast Sodium | 103 | 34 |
| Carvedilol | Carvedilol | 100 | 25 |
| Omeprazole | Omeprazole | 98 | 25 |
| Telmisartan | Telmisartan | 98 | 27 |
| Furosemide | Furosemide | 95 | 27 |
| Allopurinol | Allopurinol | 94 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 23 |
| Finasteride | Finasteride | 93 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | suppressed |
| Spironolactone | Spironolactone | 91 | 23 |
| Jardiance | Empagliflozin | 88 | 19 |
| Trazodone Hcl | Trazodone Hcl | 88 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 31 |
| Ibandronate Sodium | Ibandronate Sodium | 80 | 24 |
| Pregabalin | Pregabalin | 80 | 17 |
| Alprazolam | Alprazolam | 74 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 19 |
| Simvastatin | Simvastatin | 67 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 16 |
| Bupropion Xl | Bupropion Hcl | 64 | 13 |
| Glimepiride | Glimepiride | 63 | 17 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 63 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 59 | 41 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Famotidine | Famotidine | 57 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 54 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | suppressed |
| Meloxicam | Meloxicam | 49 | 17 |
| Clonidine Hcl | Clonidine Hcl | 48 | 12 |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 44 | 43 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 43 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 11 |
| Ozempic | Semaglutide | 42 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 41 | 14 |
| Metformin Hcl | Metformin Hcl | 40 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 39 | suppressed |
| Torsemide | Torsemide | 38 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Prednisone | Prednisone | 31 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 13 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Silodosin | Silodosin | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Estradiol | Estradiol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52.13 · 3 records | Amgen Inc. | ELIQUIS, NURTEC ODT, OTEZLA, REPATHA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error